HIV Trial Scrapped After Gel Found to Be Ineffective
November 29, 2011
A routine review of data from a large clinical trial found that a tenofovir-based vaginal gel was not effective in preventing HIV in women, researchers reported Friday.
In 2010, the CAPRISA (Center for the AIDS Program of Research in South Africa) study in South Africa found a tenofovir-based microbicide vaginal gel was 39 percent more effective than placebo gel when used before and after sex. In regular users, it was 54 percent effective. The VOICE study, begun in 2009 with 5,029 sexually active HIV-negative women in South Africa, Uganda, and Zimbabwe, was expected to back those findings. Instead, the interim data review found no difference between the tenofovir gel and placebo, with an annual HIV incidence of 6 percent in the placebo group, compared with 6.1 percent for tenofovir gel users.
Agence France Presse
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)